RTP pharma firm could get $45M if therapy targeting hearing lose due to chemo wins FDA OK
Triangle-based Fennec Pharmaceuticials has a lot riding on possible FDA approval of its new drug candidate – Pedmark. Up to $45 million, in fact.
Read More
Fennec Pharma
FDA boosts RTP firm’s proposed treatment to prevent hearing loss in children receiving chemo
An unusual therapy under development by Fennec Pharmaceuticals is getting an expedited opportunity to protect the hearing of children undergoing chemotherapy.
Read More
Fennec Pharma names gene therapy exec to its board
Fennec Pharmaceuticals Inc. has appointed biotech executive Jodi Cook to its board of directors. Here are the details.
Read More
Fennec Pharma’s new chief commerical officer lands $360K salary – and much more
Fennec Pharmaceuticals released compensation details for its newly created chief commercial officer position, according to a Securities and Exchange Commission filing.
Read More
Fennec Pharma CEO’s compensation more than doubles
The chief executive officer of biotechnology company Fennec Pharmaceuticals Inc. saw his compensation more than double in 2108 due to a significant increase in company stock option awards,according to a securities filing.
Read MoreFennec’s CEO received a 64% increase in 2017 compensation
The chief executive officer of drug development company Fennec Pharmaceuticals saw a 64 percent increase in compensation in 2017, primarily due to receiving a bonus, according to a securities filing,
Read More
FDA fast-tracks Durham firm’s drug that targets hearing loss resulting from chemotherapy
Fennec Pharmaceuticals has been granted fast track designation for its signature drug that targets loss of hearing among children who receive chemotherapy by the FDA.
Read MoreDurham pharma firm’s stock pops 23% in move to Nasdaq
Drug development company Fennec Pharmeuticals Inc. saw its stock price rise by more than 23 percent in its first day of trading on the Nasdaq. The company began trading Wednesday at $8.85 and closed at $10.90 per share. The specialty pharmaceutical company focuses on the development of Sodium Thiosulfate...
Read More
